Adagene reported 2025 results and advanced its lead program, muzastotug (ADG126), a masked anti-CTLA-4 antibody now showing dose-dependent activity with pembrolizumab in microsatellite-stable colorectal cancer. The company cited a 29% confirmed overall response rate among 21 patients at 20 mg/kg, a 19.4-month median overall survival in the 10 mg/kg cohorts with 17.8 months of follow-up, and a favorable safety profile across 67 patients with no dose-limiting toxicities or grade 4/5 treatment-related events and a 4% discontinuation rate. A randomized phase 2 dose-optimization study aligned with FDA’s Project Optimus is enrolling ahead of plan, with results expected in the first half of 2027 and a registration trial to follow once the optimal regimen is selected. Cash of $74.5 million at year-end 2025, augmented by 2026 ATM proceeds, extends runway into early 2028, with $7.7 million in 2025 collaboration revenue and reduced net loss year over year.
The strategic question is whether a dose-optimized, better-tolerated CTLA-4 can reset immunotherapy expectations in one of oncology’s most I/O-refractory settings and do so with an economic profile payers will accept. CTLA-4’s reputational baggage has long been toxicity; if masking technology reliably expands the therapeutic window, the class could be re-legitimized as a backbone, not just a niche enhancer. In MSS colorectal cancer, where PD-1 monotherapy fails and later-line standards are small-molecule therapies like fruquintinib, even a modest, durable immunotherapy response at acceptable tolerability could be practice-influencing—provided randomized data confirm survival gains versus real comparators, not historical benchmarks.
For patients and physicians, the signal matters because tolerability drives time-on-therapy, and time-on-therapy underpins durable control when CTLA-4–mediated Treg depletion and PD-1–mediated reinvigoration work in tandem. The low discontinuation and absence of high-grade immune toxicities reported so far suggest community oncologists could keep patients on combination immunotherapy longer, if safety holds in larger trials and in triplets. For payers, the bar is higher: in 3L+ MSS CRC, any price stacking from IO doublets or triplets layered on fruquintinib will demand clear, randomized overall survival and quality-of-life evidence, along with dose optimization that minimizes costly immune-related adverse events. Medical Affairs teams will need to translate early pathological response data from neoadjuvant cohorts and real-world evidence into credible narratives around patient selection, monitoring, and resource utilization.
Adagene’s 2026 American Association for Cancer Research presentations extend the thesis to triplets: muzastotug plus pembrolizumab with fruquintinib in MSS CRC, and muzastotug with atezolizumab and bevacizumab in first-line hepatocellular carcinoma within Roche’s Morpheus Liver program. These readouts test a broader industry shift toward rational triplets that pair immune modulation with anti-angiogenesis—an approach seeing renewed momentum in HCC and CRC. The company’s portfolio of collaborations with Sanofi, Roche, Exelixis, and others underscores another trend: small-cap biotechs financing longer runways with platform partnerships that generate non-dilutive revenue and external validation while sharing development risk, now increasingly shaped by Project Optimus’ demand for dose-finding rigor.
The competitive field in next-generation CTLA-4 is tightening, from masked and conditionally activated constructs to bispecific PD-1/CTLA-4 approaches, all chasing efficacy with fewer immune toxicities. If Adagene can convert early response and survival signals into a dose-optimized, payer-credible registrational package that withstands triplet toxicity scrutiny, CTLA-4 could reemerge as a foundational component in hard-to-treat tumors. The decisive test now is whether 2026–2027 readouts can demonstrate not just activity, but a differentiated safety and economic profile strong enough to shift guidelines in MSS CRC and to challenge existing IO-VEGF standards in HCC.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
